XYLT2: Potential Drug Targets and Biomarkers (G64132)

Target Name: XYLT2

NCBI ID: G64132

XYLT2: Potential Drug Targets and Biomarkers

XYLT2 (PXYLT2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a member of the PXYLT family, which includes several similar proteins that are involved in the regulation of cellular processes such as cell adhesion, migration, and angiogenesis.

One of the unique aspects of XYLT2 is its ability to interact with several different proteins, including the protein known as Focal Adhesion Navigation Molecule (FAIM), which is a protein that is involved in the regulation of cell adhesion and migration. This interaction between XYLT2 and FAIM has important implications for the development of cancer, as the regulation of cell adhesion and migration is a key aspect of tumor progression.

In addition to its interaction with FAIM, XYLT2 has also been shown to interact with several other proteins, including the protein known as PDGF-BB (Plotnikin-derived growth factor-binding protein), which is a protein that is involved in the regulation of cell proliferation and survival. This interaction between XYLT2 and PDGF-BB suggests that XYLT2 may be a drug target or biomarker for the treatment of diseases that are characterized by the uncontrolled proliferation of cells.

Another potential mechanism by which XYLT2 may be involved in the regulation of cellular processes is its role in the regulation of the blood-brain barrier (BBB). The BBB is a specialized barrier that separates the brain from the bloodstream, and it plays an important role in the exchange of nutrients, oxygen, and other substances between the brain and the bloodstream. XYLT2 has been shown to interact with the protein known as tight junction protein (TJP), which is involved in the regulation of the BBB. This interaction suggests that XYLT2 may be a drug target or biomarker for the treatment of disorders that are characterized by the disruption of the BBB.

In conclusion, XYLT2 is a protein that has been shown to interact with several different proteins, including FAIM, PDGF-BB, and TJP. These interactions suggest that XYLT2 may be a drug target or biomarker for the treatment of diseases that are characterized by the uncontrolled proliferation of cells, the disruption of the BBB, or other cellular processes. Further research is needed to determine the full implications of these interactions, and to develop effective treatments for the associated disorders.

Protein Name: Xylosyltransferase 2

Functions: Catalyzes the first step in the biosynthesis of chondroitin sulfate, heparan sulfate and dermatan sulfate proteoglycans, such as DCN. Transfers D-xylose from UDP-D-xylose to specific serine residues of the core protein

More Common Targets